Edgewise Therapeutics Inc (EWTX)
19.30
+0.29
(+1.53%)
USD |
NASDAQ |
May 02, 16:00
19.32
+0.02
(+0.10%)
After-Hours: 18:30
Edgewise Therapeutics Cash from Operations (TTM): -91.95M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -91.95M |
| September 30, 2023 | -76.97M |
| June 30, 2023 | -66.88M |
| March 31, 2023 | -62.89M |
| December 31, 2022 | -52.64M |
| September 30, 2022 | -50.20M |
| June 30, 2022 | -46.50M |
| Date | Value |
|---|---|
| March 31, 2022 | -40.02M |
| December 31, 2021 | -33.51M |
| September 30, 2021 | -28.73M |
| June 30, 2021 | -23.74M |
| March 31, 2021 | -17.95M |
| December 31, 2020 | -14.63M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-91.95M
Minimum
Dec 2023
-14.63M
Maximum
Dec 2020
-46.66M
Average
-46.50M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
| Sarepta Therapeutics Inc | -500.99M |
| PTC Therapeutics Inc | -58.17M |
| Fate Therapeutics Inc | -132.26M |
| Viking Therapeutics Inc | -54.87M |
| Regenxbio Inc | -218.41M |